3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Colorectal Neoplasms
28
Ovarian Neoplasms
16
Neoplasms
12
Fallopian Tube Neoplasms
11
Carcinoma, Hepatocellular
11
Carcinoma, Non-Small-Cell Lung
8
Colonic Neoplasms
6
Neoplasm Metastasis
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Liver Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Peritoneal Neoplasms
2
Pancreatic Neoplasms
2
Neurofibromatosis 2
2
Mouth Neoplasms
2
Meningioma
2
Lymphoid Interstitial Pneumonia
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Brenner Tumor
2
Advanced Solid Tumour
2
Vulvar Neoplasms
1
Virus Diseases
1
Interventions
pembrolizumab
7
Specimen Handling
6
Human Papillomavirus DNA Tests
4
Colposcopy
4
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
palbociclib
2
lenvatinib
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Magnetic Resonance Imaging
2
Gemcitabine
2
Biopsy
2
Bevacizumab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tisotumab vedotin
1
sapanisertib
1
ribociclib
1
relatlimab
1
pertuzumab
1
patritumab deruxtecan
1
osimertinib
1
omipalisib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Bevacizumab
×
30 days
×
Clear all
NCT07216703
2026-05-22
TroFuse-036
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,023 enrolled
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled